Free tool
FAERS Monitor: Ascor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209112 or its brand name (Ascor, Ascorbic Acid). Reports on generic versions are filed under their own applications.
Reports
23,363
Serious
16,695
71% of reports
Hospitalization
9,339
Death reported
2,648
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue2,366
- pain2,120
- nausea2,025
- diarrhoea1,860
- headache1,830
- drug ineffective1,800
- dyspnoea1,711
- off label use1,601
- vomiting1,585
- asthenia1,491
- rash1,425
- dizziness1,363
- arthralgia1,300
- pruritus1,166
- pyrexia1,162
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 369 |
| 2005 | 810 |
| 2006 | 875 |
| 2007 | 890 |
| 2008 | 1,126 |
| 2009 | 1,295 |
| 2010 | 1,093 |
| 2011 | 1,802 |
| 2012 | 1,842 |
| 2013 | 428 |
| 2014 | 485 |
| 2015 | 493 |
| 2016 | 661 |
| 2017 | 794 |
| 2018 | 1,056 |
| 2019 | 1,037 |
| 2020 | 1,325 |
| 2021 | 1,279 |
| 2022 | 1,328 |
| 2023 | 1,222 |
| 2024 | 1,306 |
| 2025 | 1,093 |
| 2026 | 753 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,030,796 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| astheniaSignal | 1,491 | 3.6 | 3.4 | 2,809 |
| painSignal | 2,120 | 3.1 | 3.0 | 3,122 |
| vomitingSignal | 1,585 | 3.0 | 2.9 | 2,212 |
| pyrexiaSignal | 1,162 | 3.0 | 2.9 | 1,599 |
| rashSignal | 1,425 | 2.9 | 2.8 | 1,867 |
| arthralgiaSignal | 1,300 | 2.8 | 2.7 | 1,552 |
| fatigueSignal | 2,366 | 2.7 | 2.6 | 2,707 |
| pruritusSignal | 1,166 | 2.7 | 2.6 | 1,303 |
| dyspnoeaSignal | 1,711 | 2.7 | 2.6 | 1,914 |
| headacheSignal | 1,830 | 2.6 | 2.5 | 1,902 |
| diarrhoeaSignal | 1,860 | 2.6 | 2.5 | 1,880 |
| dizzinessSignal | 1,363 | 2.5 | 2.3 | 1,210 |
| nauseaSignal | 2,025 | 2.3 | 2.2 | 1,552 |
| off label use | 1,601 | 1.6 | 1.6 | 423 |
| drug ineffective | 1,800 | 1.2 | 1.2 | 82 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.